UK Graves’ disease market is growing at a CAGR of around 4.1% during the forecast period. Grave’s disease is one of the most prevalent autoimmune diseases across the UK. It is one of the leading causes of hyperthyroidism in the country. The disease is caused by a number of factors including the sedentary lifestyles, changing eating pattern, the prevalence of diabetes in the country are few of the key reasons which are expected to promote the demand of treatment and diagnostic services, which in turn increases the UK Graves’ disease market. The prevalence of diabetes has increased significantly in the UK. According to The British Diabetic Association 2017, nearly 3.7 million people were diagnosed with diabetes. Amongst this 10 %, people have type-1 diabetes. As the prevalence of such disease increases in the country, the risk associated with Grave’s disease is also increasing, thereby creating opportunities for the growth of the UK Graves’ disease market during the forecast period.
Visit for Global Graves Disease Market Report at: https://www.omrglobal.com/industry-reports/graves-disease-market
Further, the prevalence of Grave’s’ disease is majorly amongst the age group of 19-54. According to Eurostat, the working-age population in the UK accounted for 64.4% of the overall population. The prevalence of Grave’s disease also increases with changes in unhealthy eating patterns and smoking practices. It is observed that smoking is one of the key reasons which promote the prevalence of Grave’s disease in the working-age population. The percentage of population smoking in the UK is majorly between the age group of 25-34. Owing to this, the prevalence of Grave’s disease is expected to increase, thereby creating opportunities for the growth of the UK Graves’ disease market.
In addition, government initiative including the European Thyroid Association that has laid down numerous guidelines for the treatment of Grave’s hyperthyroid is also augmenting the market growth. As technology advances, the adoption of the surgical process for the treatment of Grave’s disease is expected to increase significantly in the coming years. Owing to this the proportion of patients treated from thyroidectomy is more from the Grave’s disease. This is expected to promote the growth of the UK Graves’ disease market in the near future.
Research Methodology
The market study of the UK Graves’ disease market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. UK Graves’ Disease Market by Diagnosis
5.1.1. Ultrasound
5.1.2. Imaging Tests
5.1.3. Radioactive Iodine Uptake
5.1.4. Blood Sample
5.2. UK Graves’ Disease Market by Treatment
5.2.1. Anti- Thyroid Medication
5.2.2. Radioactive Iodine Therapy
5.2.3. Surgery
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. Allergan PLC
6.3. Eli Lilly and Co.
6.4. GlaxoSmithKline PLC
6.5. Johnson & Johnson
6.6. Merck & Co. Inc.
6.7. Mylan NV
6.8. Novartis International AG
6.9. Pfizer Inc.
6.10. Sanofi SA
6.11. Takeda Pharmaceutical Co. Ltd.
1. UK GRAVES’ DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2018-2025 ($ MILLION)
2. UK GRAVES’ DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
1. UK GRAVES’ DISEASE MARKET SHARE BY DIAGNOSIS, 2018 VS 2025 (%)
2. UK GRAVES’ DISEASE MARKET SHARE BY TREATMENT, 2018 VS 2025 (%)